Linda Pao
Neurology · Jupiter, FLNPI 1417973827
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (40.6%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Novo Nordisk at 46.1% of the total. 2025 is the largest year on record at $19,100, 4.5 times the $4,281 reported in 2019. Among neurology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 714 payments — averaging $53.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$18K
- Eisai Inc.$4K
- Merck$2K
- AbbVie$1K
- Novartis$1K
- E.r. Squibb & Sons, L.L.C.$1K
- plus $11K from 54 others
Across 154 payments — averaging $20,174 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1.3M
- Janssen Research & Development, LLC$1.1M
- E.r. Squibb & Sons, L.L.C.$552K
- Avid Radiopharmaceuticals, Inc.$104K
- GSK$81K
- AbbVie$44K
- plus $17K from 3 others
What the payments were for
- Consulting fees$8,83523%
- Speaking & faculty fees$2511%
- Travel & lodging$13,62736%
- Food & beverage$15,50941%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Leqembi$3,528
- ALLOWRAP$170
- ADUHELM$134
- Impella$130
- ENROUTE Transcarotid Neuroprotection System$127
- ENROUTE Transcarotid Stent System$127
- ENHANCE Transcarotid Peripheral Access Kit$127
- ENROUTE 0.014 Guidewire$127
- Qutenza$124
- XARELTO$123
- KISUNLA$123
- CLEVIPREX$122
- NUPLAZID$122
- APONVIE$122
- Zynrelef$122
- GIAPREZA$121
- AIMOVIG$116
- UBRELVY$102
- RYTARY$102
How this compares
$38,240 in reported general payments places this provider in the 90th percentile of 1,434 neurology providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 18 | $5,825 |
| Rasagiline Mesylate | 12 | $1,708 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 12 | $685 |
| Venlafaxine Hcl | 12 | $310 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 12 | $99 |
| Zolpidem Tartrate | 12 | $92 |
| Rosuvastatin Calcium | 12 | $65 |
Paid to pharmacies, not to this prescriber.
Other neurology in Jupiter
- Jennifer BuczynerJupiter$416K
- Stuart IsaacsonBoca Raton$3.9M
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
- David RoseTampa$1.4M
- Matthew BakerNaples$1.4M
- Donald NegroskiSarasota$1.4M
- Mark CascioneTampa$1.2M
- Lance KimOcala$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.